IFNA1 and neoplasm: In our most recent study, Tang et al. demonstrated that anti-PD-L1 is significantly accumulated in tumors after systemic treatment and could be utilized to deliver immunomodulatory molecules (Tang et al.2018), such as IFN–anti-PD-L1, specifically into tumor tissues (unpublished data from Yang-Xin Fu’s group).